ArticleScientific reports2025
A comparative analysis of collagen based dressings and polysaccharide microspheres for hemostasis management in hepatic stab wounds.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to evaluate two of the most commonly used products, the collagen-based patch (Hemopatch) and the micropolysaccharide microspheres powder (Perclot), in the context of stab liver injury in pigs. The objectives of this study were to assess blood loss at various time intervals up to 24 h, survival rates, and mean arterial pressure. The research involved 18 Large-White swine. The animals underwent a traumatic liver puncture through two 5 cm deep blade incisions that severed two main suprahepatic veins. Hemostatic surgical treatment was conducted for 12 min using two hemostatic agents. In the first 3 min after injury, the Hemopatch group lost less blood than the Perclot group, with 300 cc (222.5-415.0) compared to 555.0 cc (480.0-632.5) (p = 0.001). However, at 13-60 min post-injury, the Perclot group lost less blood than the Hemopatch group, 45.0 cc (32.5-135.0) compared to 305.0 cc (112.5-607.5) (p = 0.015). Lastly, the survival rate 24 h after injury was higher in the Perclot group (88.8%) compared to the Hemopatch group (44.4%) (p = 0.046). Several disparities were observed between Perclot and Hemopatch. Although Hemopatch demonstrates prompt bleeding reduction in the initial 3 min, Perclot is capable of stabilizing the clot and subsequently reducing long-term bleeding, ultimately increasing the likelihood of survival. These observations support the utilization of Perclot for managing severe hepatic hemorrhage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.